Cytokinetics pharmaceuticals stock
WebNov 3, 2024 · Cytokinetics (CYTK) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.19. This compares to loss of $0.95 per share a year ago. WebNov 30, 2024 · PDUFA Target Action Date Set for November 30, 2024. FDA is Currently Not Planning to Hold an Advisory Committee Meeting to Discuss the Application SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food & Drug Administration (FDA) has …
Cytokinetics pharmaceuticals stock
Did you know?
WebApr 6, 2024 · Company. Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for debilitating diseases. It is developing small molecule drug candidates specifically engineered to impact muscle function and … WebDec 20, 2024 · The CSPAs provide for the sale and issuance to the RTW Investors of 511,182 shares of Cytokinetics common stock of (the "Shares") with an aggregate purchase price of $20.0 million at a price per share of $39.125. The closing will occur on December 20, 2024.
WebCytokinetics is led by a team of seasoned industry veterans with the shared objective to create the next great biopharmaceutical company that has the potential to change patients’ lives. With significant depth of industry experience and highly complementary skills in diverse fields including drug discovery, clinical research, business ... WebApr 5, 2024 · About Cytokinetics (NASDAQ:CYTK) Stock. Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and …
WebApr 9, 2024 · Shares of Cytokinetics stock opened at $36.42 on Friday. The firm’s 50-day moving average price is $39.79 and its two-hundred day moving average price is $42.22. The company has a market ...
WebApr 9, 2024 · Cytokinetics Trading Up 0.7 %. Cytokinetics stock opened at $36.42 on Friday. The business’s 50 day simple moving average is $39.79 and its 200 day simple moving average is $42.22.
WebApr 10, 2024 · Zacks Equity Research. April 10, 2024, 9:23 AM · 3 min read. It has been a rough year so far for late-stage biopharmaceutical company, Cytokinetics, Incorporated … citizenship 101WebMar 31, 2024 · Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) SOUTH SAN FRANCISCO, Calif. , April 03, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) … citizenship 1300t formWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Our Vision Leadership … dickey\\u0027s thanksgiving dinnerWebCytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing muscle activators and inhibitors. Investors & Media Cytokinetics’ unparalleled expertise has kept it at the forefront of drug discovery and development for diseases impacting muscle performance. Investor Overview Stock … citizenship 15 markerWebCytokinetics Inc (CYTK) Stock Price Today, News, Quotes, FAQs and Fundamentals 3rd Party Ad. Not an offer or recommendation by Stocktwits. See disclosure here. CYTK Cytokinetics Inc 3,105 $33.36 $0.27 (0.80%) Today Sentiment 0.00% Message Vol. 42.11% Volume (M) 720,685.00 52-Wk High $55.80 52-Wk Low $33.37 About Feed … citizens high yield savings accounts 2023WebApr 10, 2024 · Large Cap Pharmaceuticals stocks are, on average, holding a PEG ratio of 1.73 based on yesterday's closing prices. The Large Cap Pharmaceuticals industry is part of the Medical sector. citizens hillsboroWebApr 10, 2024 · CYTK Stock Overview. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing … citizens hingham ma